87 related articles for article (PubMed ID: 22032800)
21. Thrombin activatable fibrinolysis inhibitor (TAFI) is not associated with recurrent miscarriage.
Sezer SD; Baz A; Küçük M; Odabaşi AR; Serter M; Yüksel H
Clin Exp Obstet Gynecol; 2011; 38(3):228-31. PubMed ID: 21995152
[TBL] [Abstract][Full Text] [Related]
22. Plasma thrombin-activatable fibrinolysis inhibitor and plasminogen activator inhibitor-1 levels in inflammatory bowel disease.
Koutroubakis IE; Sfiridaki A; Tsiolakidou G; Coucoutsi C; Theodoropoulou A; Kouroumalis EA
Eur J Gastroenterol Hepatol; 2008 Sep; 20(9):912-6. PubMed ID: 18794606
[TBL] [Abstract][Full Text] [Related]
23. Thrombin activatable fibrinolysis inhibitor (TAFI) in human amniotic fluid. A preliminary study.
Uszyński W; Uszyński M; Zekanowska E
Thromb Res; 2007; 119(2):241-5. PubMed ID: 16540154
[TBL] [Abstract][Full Text] [Related]
24. Thrombin activatable fibrinolysis inhibitor (TAFI): relationship to hemostatic alteration in patients with beta-thalassemia.
Mokhtar GM; Matter RM; Shawki H; Abdel Aziz MM
Pediatr Hematol Oncol; 2010 Aug; 27(5):363-73. PubMed ID: 20670166
[TBL] [Abstract][Full Text] [Related]
25. Absolute risk of venous and arterial thromboembolism in thrombophilic families is not increased by high thrombin-activatable fibrinolysis inhibitor (TAFI) levels.
Folkeringa N; Coppens M; Veeger NJ; Bom VJ; Middeldorp S; Hamulyak K; Prins MH; Büller HR; van der Meer J
Thromb Haemost; 2008 Jul; 100(1):38-44. PubMed ID: 18612536
[TBL] [Abstract][Full Text] [Related]
26. TAFI activity and antigen plasma levels are not increased in acute coronary artery disease patients admitted to a coronary care unit.
Paola Cellai A; Antonucci E; Alessandrello Liotta A; Fedi S; Marcucci R; Falciani M; Giglioli C; Abbate R; Prisco D
Thromb Res; 2006; 118(4):495-500. PubMed ID: 16318869
[TBL] [Abstract][Full Text] [Related]
27. Association of genotypes of thrombin-activatable fibrinolysis inhibitors with thrombotic microangiopathies--a pilot study.
Sucker C; Hetzel GR; Farokhzad F; Dahhan F; Schmitz M; Kurschat C; Grabensee B; Maruhn-Debowski B; Zotz R; Scharf R
Nephrol Dial Transplant; 2007 May; 22(5):1347-50. PubMed ID: 17327284
[TBL] [Abstract][Full Text] [Related]
28. Thrombin activatable fibrinolysis inhibitor (TAFI) in stable angina pectoris patients undergoing coronary artery bypass grafting (CABG).
Lisowski P; Małyszko J; Hirnle T; Lisowska A; Jackowski R; Małyszko JS; Buzun L; Myśliwiec M
Rocz Akad Med Bialymst; 2005; 50():166-72. PubMed ID: 16358959
[TBL] [Abstract][Full Text] [Related]
29. High thrombin activatable fibrinolysis inhibitor levels are associated with an increased risk of premature peripheral arterial disease.
de Bruijne EL; Gils A; Rijken DC; de Maat MP; Guimarães AH; Poldermans D; Declerck PJ; Leebeek FW
Thromb Res; 2011 Mar; 127(3):254-8. PubMed ID: 21195459
[TBL] [Abstract][Full Text] [Related]
30. Identification of polymorphisms in the 5'-untranslated region of the TAFI gene: relationship with plasma TAFI levels and risk of venous thrombosis.
Franco RF; Fagundes MG; Meijers JC; Reitsma PH; Lourenço D; Morelli V; Maffei FH; Ferrari IC; Piccinato CE; Silva WA; Zago MA
Haematologica; 2001 May; 86(5):510-7. PubMed ID: 11410415
[TBL] [Abstract][Full Text] [Related]
31. [Study on the association of thrombin activatable fibrinolysis inhibitor and the Thr325Ile and Thr147Ala polymorphisms of its encoding gene CPB2 in patients with coronary heart disease].
Xu CW; Wang LL; Wu XB; Zhao JJ; Du YM; Jiang CY
Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2008 Aug; 25(4):438-42. PubMed ID: 18683146
[TBL] [Abstract][Full Text] [Related]
32. Thrombin activatable fibrinolysis inhibitor activation peptide shows association with all major subtypes of ischemic stroke and with TAFI gene variation.
Ladenvall C; Gils A; Jood K; Blomstrand C; Declerck PJ; Jern C
Arterioscler Thromb Vasc Biol; 2007 Apr; 27(4):955-62. PubMed ID: 17272741
[TBL] [Abstract][Full Text] [Related]
33. TAFI deficiency in liver cirrhosis: relation with plasma fibrinolysis and survival.
Gresele P; Binetti BM; Branca G; Clerici C; Asciutti S; Morelli A; Semeraro N; Colucci M
Thromb Res; 2008; 121(6):763-8. PubMed ID: 17915296
[TBL] [Abstract][Full Text] [Related]
34. The effect of genetic variants in the thrombin activatable fibrinolysis inhibitor (TAFI) gene on TAFI-antigen levels, clot lysis time and the risk of venous thrombosis.
Martini CH; Brandts A; de Bruijne EL; van Hylckama Vlieg A; Leebeek FW; Lisman T; Rosendaal FR
Br J Haematol; 2006 Jul; 134(1):92-4. PubMed ID: 16803573
[TBL] [Abstract][Full Text] [Related]
35. Plasma thrombin-activatable fibrinolysis inhibitor as an indicator of inflammation and disease severity in acute pancreatitis.
Sayilir A; Beyazit Y; Yesil Y; Albayrak M; Ekiz F; Celik T; Suvak B; Torun S; Ibiş M
Clin Res Hepatol Gastroenterol; 2012 Oct; 36(5):498-504. PubMed ID: 22230218
[TBL] [Abstract][Full Text] [Related]
36. Thrombin activatable fibrinolysis inhibitor (TAFI): a role in pre-eclampsia?
Dusse LM; Cooper AJ; Lwaleed BA
Clin Chim Acta; 2007 Mar; 378(1-2):1-6. PubMed ID: 17184758
[TBL] [Abstract][Full Text] [Related]
37. Genetic variation in thrombin-activatable fibrinolysis inhibitor (TAFI) is associated with the risk of splanchnic vein thrombosis.
de Bruijne EL; Darwish Murad S; de Maat MP; Tanck MW; Haagsma EB; van Hoek B; Rosendaal FR; Janssen HL; Leebeek FW;
Thromb Haemost; 2007 Feb; 97(2):181-5. PubMed ID: 17264944
[TBL] [Abstract][Full Text] [Related]
38. Clot lysis time and thrombin activatable fibrinolysis inhibitor in severe preeclampsia with or without associated antiphospholipid antibodies.
Martínez-Zamora MA; Tassies D; Carmona F; Espinosa G; Cervera R; Reverter JC; Balasch J
J Reprod Immunol; 2010 Nov; 86(2):133-40. PubMed ID: 20594598
[TBL] [Abstract][Full Text] [Related]
39. Thrombin activatable fibrinolysis inhibitor: at the nexus of fibrinolysis and inflammation.
Colucci M; Semeraro N
Thromb Res; 2012 Mar; 129(3):314-9. PubMed ID: 22113149
[TBL] [Abstract][Full Text] [Related]
40. Increased thrombin-activatable fibrinolysis inhibitor antigen levels as a clue for prothrombotic state in polycystic ovary syndrome.
Karakurt F; Gumus II; Bavbek N; Kargili A; Koca C; Selcoki Y; Ozbek M; Kosar A; Akcay A
Gynecol Endocrinol; 2008 Sep; 24(9):491-7. PubMed ID: 18958767
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]